ES2158537T3 - Derivados de acidos ciclopropilalcanoicos. - Google Patents

Derivados de acidos ciclopropilalcanoicos.

Info

Publication number
ES2158537T3
ES2158537T3 ES97915937T ES97915937T ES2158537T3 ES 2158537 T3 ES2158537 T3 ES 2158537T3 ES 97915937 T ES97915937 T ES 97915937T ES 97915937 T ES97915937 T ES 97915937T ES 2158537 T3 ES2158537 T3 ES 2158537T3
Authority
ES
Spain
Prior art keywords
cyclopropilalcanoic
derivatives
acids
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97915937T
Other languages
English (en)
Inventor
Barbara B Chen
Helen Y Chen
Michael Clare
Shashidhar N Rao
Mark A Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2158537T3 publication Critical patent/ES2158537T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN TIPO DE COMPUESTOS REPRESENTADOS MEDIANTE LA FORMULA (I), O A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS COMPUESTOS, Y A METODOS DE INHIBICION O ANTAGONIZACION SELECTIVA DE LA INTEGRINA AL V BE 3.
ES97915937T 1996-03-29 1997-03-20 Derivados de acidos ciclopropilalcanoicos. Expired - Lifetime ES2158537T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1441196P 1996-03-29 1996-03-29

Publications (1)

Publication Number Publication Date
ES2158537T3 true ES2158537T3 (es) 2001-09-01

Family

ID=21765323

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97915937T Expired - Lifetime ES2158537T3 (es) 1996-03-29 1997-03-20 Derivados de acidos ciclopropilalcanoicos.

Country Status (12)

Country Link
US (1) US5773644A (es)
EP (1) EP0889875B1 (es)
JP (1) JP2000507575A (es)
AT (1) ATE202337T1 (es)
AU (1) AU2323897A (es)
CA (1) CA2250695A1 (es)
DE (1) DE69705300T2 (es)
DK (1) DK0889875T3 (es)
ES (1) ES2158537T3 (es)
GR (1) GR3036253T3 (es)
PT (1) PT889875E (es)
WO (1) WO1997036858A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
WO1999052872A1 (en) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
JP2002522504A (ja) * 1998-08-13 2002-07-23 ジー・ディー・サール・アンド・カンパニー 多価ａｖｂ３および転移関連レセプター・リガンド
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha OMEGA-AMINO-ALPHA-HYDROXY-CARBONIC ACID DERIVATIVES WITH AN INTEGRIN ALPHA V BETA ANTAGONISM
DE19940389A1 (de) * 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selektive Inhibitoren des Urokinase-Plasminogen Aktivators
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1250935A1 (en) * 2000-01-25 2002-10-23 Meiji Seika Kaisha Ltd. REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST
DE60141889D1 (de) * 2000-02-03 2010-06-02 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
UY26780A1 (es) * 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
WO2002002522A1 (en) * 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
US20040043988A1 (en) * 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
EP1596884A2 (en) * 2003-01-30 2005-11-23 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
WO2005051890A1 (en) * 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
MX2011008936A (es) 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
US8765820B2 (en) * 2010-04-20 2014-07-01 Universita Degli Studi Di Roma “La Sapienza” Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1905813A1 (de) * 1968-07-04 1970-03-05 Akad Wissenschaften Ddr 3- oder 4-Guanidobenzoesaeurebenzyl- oder -phenylestern und deren Verwendung als Inhibitoren
FR2456731A1 (fr) * 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
ES2039356T3 (es) * 1985-11-12 1993-10-01 Ono Pharmaceutical Co., Ltd. Un procedimiento para la preparacion de derivados del acido p-guanidinobenzoico.
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
WO1992008464A1 (en) * 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
ATE227567T1 (de) * 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption

Also Published As

Publication number Publication date
WO1997036858A1 (en) 1997-10-09
PT889875E (pt) 2001-10-30
EP0889875B1 (en) 2001-06-20
DE69705300D1 (de) 2001-07-26
JP2000507575A (ja) 2000-06-20
GR3036253T3 (en) 2001-10-31
ATE202337T1 (de) 2001-07-15
AU2323897A (en) 1997-10-22
DK0889875T3 (da) 2001-09-03
DE69705300T2 (de) 2002-05-02
EP0889875A1 (en) 1999-01-13
CA2250695A1 (en) 1997-10-09
US5773644A (en) 1998-06-30

Similar Documents

Publication Publication Date Title
DE69705300D1 (de) Cyclopropylalkansäurederivate
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
AU2337197A (en) Cinnamic acid derivatives and their use as integrin antagonists
AU2337097A (en) Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
IL124537A0 (en) Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
ES2120728T3 (es) Inhibidores de la agregacion de plaquetas.
DE69332259D1 (de) Kondensierte Thiadiazolderivate, Verfahren zu ihrer Herstellung und deren Verwendung
ES2115760T3 (es) Derivados de 4''-desoxieritromicina.
DE69330601D1 (de) Serotoninergische ergolin derivate
MX9806229A (es) Derivados de benzo(c)quinolicina, su preparacion y uso como inhibidores de la 5alfa-reductasas.
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 889875

Country of ref document: ES